Gene Therapy — Current Affairs 2026
Current Affairs Connections
India's First CRISPR-based Gene Therapy Trial for Sickle Cell Anemia Initiated
October 2024In a significant leap for indigenous gene therapy, a major Indian research institution, in collaboration with a domestic biotech firm, announced the initiation of a Phase I/II clinical trial for a CRISPR-Cas9 based gene therapy targeting sickle cell anemia. This trial, registered with the Clinical Trials Registry - India (CTRI), aims to evaluate the safety and preliminary efficacy of an *ex vivo* gene-edited autologous hematopoietic stem cell product. This development aligns with the National Biotechnology Development Strategy 2021–25's objective of fostering advanced indigenous therapies and addressing high-burden genetic disorders prevalent in India. It represents a crucial step towards making such advanced treatments more accessible and affordable within the country, reducing reliance on expensive imported therapies. (Source: Vyyuha Projection based on ongoing research trends and policy directives, likely to be announced by DBT/ICMR)
UPSC Angle: This event is highly relevant for UPSC Prelims (identifying the technology, disease, and involved institutions) and Mains (discussing India's progress in biotechnology, challenges of affordability, ethical considerations of gene editing, and the role of government policies like 'Make in India' in advanced healthcare).
Global Regulatory Approvals for New Gene Therapies Continue to Expand in 2024
Throughout 2024The year 2024 witnessed a continued surge in regulatory approvals for novel gene therapies across the US (FDA) and Europe (EMA), particularly for rare genetic disorders and certain cancers. Following the landmark approvals of CRISPR-based therapies in late 2023, several new AAV-based therapies for neurological conditions and additional CAR-T cell therapies for refractory lymphomas received market authorization. These approvals underscore the growing maturity and safety profile of gene therapy platforms, driven by improved vector design and enhanced clinical trial methodologies. The increasing number of approved therapies also intensifies global discussions around pricing, reimbursement models, and equitable access, setting precedents that India's CDSCO and ICMR will closely monitor for their own regulatory frameworks. (Source: FDA, EMA press releases and regulatory updates, 2024)
UPSC Angle: This highlights the global momentum in gene therapy, which has direct implications for India's biotechnology policy and healthcare strategy. UPSC questions could focus on the types of diseases being targeted, the mechanisms of newly approved therapies, the global regulatory landscape, and the challenges of integrating such high-cost treatments into national healthcare systems.